Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy

NCT06614985 is registered in ClinicalTrials.gov with Renmin Hospital of Wuhan University as lead sponsor.

NCT NCT06614985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06614985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy
Lead sponsor
Renmin Hospital of Wuhan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 20, 2024
Completion date
October 1, 2027
Enrollment
172 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary membranous nephropathy